ปัจจัยที่สัมพันธ์กับการเข้าสู่ภาวะโรคสงบในเด็กที่มีภาวะ Isolated Thrombocytopenia: การศึกษาแบบย้อนหลังในโรงพยาบาลวชิระภูเก็ต

Anuchit  Choowet

Authors

Anuchit Choowet Department of Pediatrics Vachira Phuket Hospital

Keywords:

Isolated thrombocytopenia, Remission, Children, Associated factors

Abstract

Background: Most children with isolated thrombocytopenia achieve remission within 12 months. However, approximately 20–25% have persistent thrombocytopenia and progress to chronic immune thrombocytopenia (ITP). Data on factors associated with remission among Thai pediatric patients remain limited.

Objective: To identify factors associated with remission in children younger than 15 years who were initially diagnosed with isolated thrombocytopenia at Vachira Phuket Hospital.

Methods: This retrospective cohort study reviewed the medical records of 90 children younger than 15 years who were initially diagnosed with isolated thrombocytopenia at Vachira Phuket Hospital between 2020 and 2025. Demographic, clinical, and laboratory data were collected. Descriptive statistics were used to summarize the data. Factors associated with remission were analyzed using univariable and multivariable logistic regression analyses. Results are presented as odds ratios (ORs) with 95% confidence intervals (95% CIs).

Results: A total of 90 patients were included. Fifty-four patients (60.0%) achieved remission within 3 months after diagnosis, and an additional 9 patients (10.0%) achieved remission between 3 and 12 months after diagnosis. Twenty-seven patients (30.0%) had persistent thrombocytopenia beyond 12 months. However, two patients with chronic ITP subsequently achieved remission after 12 months. Overall, 65 patients (72.2%) achieved remission, while 25 patients (27.8%) did not achieve remission. Multivariable logistic regression analysis showed that male sex was independently associated with remission (adjusted OR 3.76, 95% CI 1.23–11.46; p=0.020)

Conclusion: Male sex was independently associated with remission in children initially presenting with isolated thrombocytopenia.

References

Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009 Mar 12;113(11):2386–93. doi:10.1182/blood-2008-07-162503 PubMed PMID: 19005182.

Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019 Dec 10;3(23):3829–66. doi:10.1182/bloodadvances.2019000966 PubMed PMID: 31794604; PubMed Central PMCID: PMC6963252.

Audia S, Mahévas M, Nivet M, Ouandji S, Ciudad M, Bonnotte B. Immune Thrombocytopenia: Recent Advances in Pathogenesis and Treatments. Hemasphere. 2021 Jun;5(6):e574. doi:10.1097/HS9.0000000000000574 PubMed PMID: 34095758; PubMed Central PMCID: PMC8171374.

Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN. The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports. Am J Hematol. 2010 Mar;85(3):174–80. doi:10.1002/ajh.21616 PubMed PMID: 20131303.

Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019 Nov 26;3(22):3780–817. doi:10.1182/bloodadvances.2019000812 PubMed PMID: 31770441; PubMed Central PMCID: PMC6880896.

Faki Osman ME. Childhood immune thrombocytopenia: Clinical presentation and management. Sudan J Paediatr. 2012;12(1):27–39. PubMed PMID: 27493327; PubMed Central PMCID: PMC4949815.

Grainger JD, Young NL, Blanchette VS, Klaassen RJ. Quality of life in immune thrombocytopenia following treatment. Arch Dis Child. 2013 Nov;98(11):895–7. doi:10.1136/archdischild-2013-303784 PubMed PMID: 23956257.

Mathias SD, Gao SK, Miller KL, Cella D, Snyder C, Turner R, et al. Impact of chronic Immune Thrombocytopenic Purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective. Health Qual Life Outcomes. 2008 Feb 8;6:13. doi:10.1186/1477-7525-6-13 PubMed PMID: 18261217; PubMed Central PMCID: PMC2275726.

Cheng CN, Yang YN, Yeh YH, Chen LW, Chen JS, Lin YC. Predictors of Remission in Severe Childhood Immune Thrombocytopenia. Diagnostics (Basel). 2023 Jan 17;13(3):341. doi:10.3390/diagnostics13030341 PubMed PMID: 36766447; PubMed Central PMCID: PMC9914323.

Bennett CM, Neunert C, Grace RF, Buchanan G, Imbach P, Vesely SK, et al. Predictors of remission in children with newly diagnosed immune thrombocytopenia: Data from the Intercontinental Cooperative ITP Study Group Registry II participants. Pediatric Blood & Cancer. 2018;65(1):e26736. doi:10.1002/pbc.26736

Chotsampancharoen T, Sripornsawan P, Duangchoo S, Wongchanchailert M, McNeil E. Predictive factors for resolution of childhood immune thrombocytopenia: Experience from a single tertiary center in Thailand. Pediatr Blood Cancer. 2017 Jan;64(1):128–34. doi:10.1002/pbc.26178 PubMed PMID: 27571705.

Chotsampancharoen T, Sripornsawan P, Duangchoo S, Wongchanchailert M, McNeil E. Clinical outcome of childhood chronic immune thrombocytopenia: A 38-year experience from a single tertiary center in Thailand. Pediatr Blood Cancer. 2017 Nov;64(11). doi:10.1002/pbc.26598 PubMed PMID: 28453897.

Alpdoğan S, Gülen H, Alpdoğan S, Gülen H. Assessment of Clinical and Laboratory Predictors for Chronic Childhood Immune Thrombocytopenia. The Journal of Pediatric Research. 2023 Dec 28. doi:10.4274/jpr.galenos.2023.06992

Heitink-Pollé KMJ, Nijsten J, Boonacker CWB, de Haas M, Bruin MCA. Clinical and laboratory predictors of chronic immune thrombocytopenia in children: a systematic review and meta-analysis. Blood. 2014 Nov 20;124(22):3295–307. doi:10.1182/blood-2014-04-570127 PubMed PMID: 25305206.

Revel-Vilk S, Yacobovich J, Frank S, Ben-Ami T, Yechieli M, Shkalim V, et al. Age and Duration of Bleeding Symptoms at Diagnosis Best Predict Resolution of Childhood Immune Thrombocytopenia at 3, 6, and 12 Months. The Journal of Pediatrics. 2013 Nov 1;163(5):1335-1339.e2. doi:10.1016/j.jpeds.2013.06.018